Orexo to Participate in Annual Healthcare Conference
Orexo AB (Publ.), listed on the Stockholm Stock Exchange under the ticker 'ORX' and with ADRs available on OTCQX (Ticker: ORXOY), is pleased to announce its participation in Pareto Securities' 15th Annual Healthcare Conference. This important event is set for September 19 and will take place at the Downtown Camper by Scandic, right in the city center.
Details of the Conference and Presentation
At the conference, Orexo will showcase a presentation led by Robert Rönn, who serves as Senior Vice President and Head of Research and Development (R&D). His presentation is scheduled for 2:25 PM to 2:45 PM CET in the Event Small room. After the presentation, attendees will have the chance to engage in one-on-one meetings with both Robert Rönn and Lena Wange, the Director of Investor Relations, facilitating in-depth discussions about Orexo's innovative projects.
About Orexo
With nearly 30 years of experience, Orexo has made a significant mark in the pharmaceutical sector by developing advanced treatments that cater to critical medical needs. The company primarily focuses on areas such as opioid use disorder, providing essential treatment solutions for patients. Orexo has achieved impressive net sales of SEK 624 million in the last fiscal year, supported by a dedicated team of 126 employees.
Innovative Pharmaceuticals and Therapeutic Areas
Orexo is well-known for its dedication to delivering innovative therapeutic solutions across various medical fields. The company actively collaborates with leading organizations to develop and commercialize products globally, ensuring that patients have access to the best treatment options available.
Financial Overview
Orexo's financial health remains robust, as evidenced by its net sales and strategic growth initiatives. Being listed on Nasdaq Stockholm and offering ADRs on OTCQX enhances accessibility for investors both domestically and internationally.
Advanced Drug Delivery Technology: AmorphOX
A key highlight of Orexo’s innovation portfolio is its AmorphOX® drug delivery technology. This advanced formulation system combines a unique mix of active ingredients and carrier materials to create a stable amorphous composite, which allows for rapid dissolution and effective drug absorption. AmorphOX technology has demonstrated promising outcomes in various clinical studies, improving patient treatment experiences.
Clinical Studies and Validation
The effectiveness of AmorphOX has been confirmed through numerous human clinical trials, showcasing its potential to significantly enhance drug exposure. This technology accommodates a wide range of active ingredients, positioning Orexo at the forefront of pharmaceutical development.
Future Directions
Looking ahead, Orexo is committed to expanding its research efforts and exploring new therapeutic areas. This ongoing dedication to addressing unmet medical needs ensures that Orexo remains a vital player in the pharmaceutical landscape.
Connect with Orexo
If you're interested in discovering more about Orexo's latest developments, the company encourages you to visit their official website at www.orexo.com. Additionally, Orexo is active on platforms such as LinkedIn, X, and YouTube, where they share updates about their initiatives and accomplishments.
Contact Information
For further inquiries, please reach out to:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
Phone: +46 18 780 88 00
Email: [email protected]
Frequently Asked Questions
What is Orexo's primary focus in the pharmaceutical industry?
Orexo is dedicated to developing innovative treatments, especially for opioid use disorder, and aims to address significant medical needs on a global scale.
When will Orexo present at the conference?
Orexo's presentation by Robert Rönn is scheduled for September 19, from 2:25 PM to 2:45 PM CET.
How can investors find out more about Orexo's financial performance?
Investors can visit Orexo's official website to access their financial reports and updates regarding their business activities.
What is AmorphOX technology?
AmorphOX is Orexo’s proprietary drug delivery system that enhances the rapid dissolution and stability of active pharmaceutical ingredients, validated through clinical studies.
Where can I find more information about Orexo's product pipeline?
Comprehensive information about Orexo's product pipeline and developments is available on their website and through their investor relations announcements.
